RIN Rii

RNS Number:8317I
RII PLC
21 February 2005

February 21 2005



RII plc ("the company")
Result of EGM



RII shareholders approve EGM resolutions


Shareholders in RII plc today approved all the resolutions for the company to
raise #3.0million, to acquire BioPartners Limited ("BioPartners") and to change
the name of the company to Minster Pharmaceuticals plc (Minster).



Application has been made to the London Stock Exchange for the resultant
enlarged share capital to be admitted to trading on AIM and dealings are
expected to commence on Friday, 25th February 2005.



Minster is developing compounds for the treatment and prevention of migraine and
for the treatment of chronic schizophrenia.



Paul Sharpe, who has been appointed Chairman and Chief Executive of Minster,
said: " We are in a strong position to address the very large markets that exist
for migraine and for schizophrenia and so to generate value for our shareholders
as we move our compounds closer towards clinical use."



Robert Stubbs, who is stepping down as Chairman of the Company but continuing as
a non-executive director, said: "We are delighted to have acquired BioPartners
and thank our shareholders for their support. We look forward to the future with
confidence"



ENDS





For further information, please contact

Cubitt Consulting
Michael Henman
020 7367 5106


Minster Pharmaceuticals plc
Dr Paul Sharpe
Chairman/CEO
01799 506623


Minster Pharmaceuticals plc
Robert Stubbs
Director
020 7355 4071



Insinger de Beaufort
Jeremy King
Stephen Goschalk
020 7190 7000




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

REGTBMTTMMBTBBA

Rii (LSE:RIN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Rii (LSE:RIN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024